AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11171733
Drug: Filgrastim (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (300 microg) administered IV daily for up to 5 days
Trial: 11171733
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV daily for up to 5 days
Trial: 9665023
Drug: 5% solution
RxNorm normalized name: Introl 75% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% solution of glucose (Control)
Trial: 31994271
Drug: TPF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF chemotherapy and PI3K-AKT-mTOR inhibitors
Trial: 25784079
Drug: Daily meditation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meditation for six weeks (treatment group)
Trial: 21619828
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg simvastatin, taken in evening for 4 months
Trial: 16753449
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 10 ml) biweekly for 12 weeks
Trial: 9663366
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 150 mg/d (150 mg QD)
Trial: 9663366
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 300 mg/d (150 mg BID)
Trial: 3046791
Drug: darodipine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darodipine 100 mg twice a day
Trial: 3046791
Drug: darodipine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darodipine 150 mg twice a day
Trial: 29611518
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of oxaliplatin-containing chemotherapy
Trial: 29611518
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of oxaliplatin-containing chemotherapy
Trial: 25843292
Drug: Ag-DC-CIK immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag-DC-CIK immunotherapy
Trial: 25843292
Drug: CIK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK treatment
Trial: 25843292
Drug: Ag-DC-CIK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag-DC-CIK treatment
Trial: 21865087
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine (Cervarix, GlaxoSmithKline)
Trial: 18545693
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion
Trial: 15262119
Drug: Intraperitoneal IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal IL-2 therapy
Trial: 2192383
Drug: cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive and behaviour therapy
Trial: 25832687
Drug: Concurrent chemo-radiation
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-radiation alone (control)
Trial: 19654536
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir administered during the first 6 months after penetrating keratoplasty
Trial: 15536141
Drug: Intraperitoneal cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg)
Trial: 15536141
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (Phase I)
Trial: 8261298
Drug: Urethral plug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral plug treatment
Trial: 3899047
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitors (MAOIs) - clorgyline or tranylcypromine sulfate
Trial: 24298907
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (clarithromycin and ethambutol)
Trial: 22116196
Drug: Allopurinol (100‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100‐300 mg/day)
Trial: 17440125
Drug: Traditional weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Traditional weekly sessions
Trial: 16138585
Drug: Huorongbushen 48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huorongbushen 48 g daily for 3 months
Trial: 23609398
Drug: olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine (10 mg)
Trial: 12503835
Drug: thioridazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thioridazine (50 mg)
Trial: 1671890
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (antibacterial agents withdrawn)
Trial: 1671890
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antibacterial therapy (without candida overgrowth)
Trial: 6186329
Drug: Intravenous atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atenolol followed by oral atenolol (5 mg IV, then 50 mg oral, 50 mg oral 12 hours later, then 100 mg daily for 10 days)
Trial: 6105436
Drug: Intravenous atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atenolol
Trial: 10092302
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg urease + 5 microg heat-labile enterotoxin (LT)
Trial: 10092302
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg urease + 5 microg heat-labile enterotoxin (LT)
Trial: 10092302
Drug: Urease (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urease (any dose)
Trial: 2538050
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or 15 g of soy polysaccharide fiber
Trial: 2538050
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of soy polysaccharide fiber
Trial: 140827
Drug: Tofranil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofranil (25 mg three times a day for four weeks)
Trial: 28585859
Drug: Patiromer 25.2
RxNorm normalized name: patiromer 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 25.2 g coadministered with levothyroxine
Trial: 28585859
Drug: Patiromer 25.2
RxNorm normalized name: patiromer 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 25.2 g coadministered with metformin
Trial: 28585859
Drug: Patiromer 25.2
RxNorm normalized name: patiromer 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 25.2 g coadministered with ciprofloxacin
Trial: 28585859
Drug: Patiromer 25.2
RxNorm normalized name: patiromer 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 25.2 g coadministered with various drugs
Trial: 28585859
Drug: Patiromer 25.2
RxNorm normalized name: patiromer 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 25.2 g coadministered with ciprofloxacin, levothyroxine, and metformin
Trial: 25749297
Drug: Darapladib 160
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib 160 mg once daily for 3 months
Trial: 23807837
Drug: Multimodal microemulsion
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal microemulsion (formulation A)
Trial: 23807837
Drug: Minoxidil alone
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minoxidil alone (formulation B)
Trial: 23807837
Drug: Placebo (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (formulation C)
Trial: 12584283
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (initial dose: 2.4 g/day, increased to 4.4 g/day)
Trial: 12584283
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (4.8 g/day)
Trial: 11357004
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH treatment (0.3 IU/kg) interrupted
Trial: 1589558
Drug: Ethanol 0.9
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.9 g/kg body weight
Trial: 2895705
Drug: Flunitrazepam 1
RxNorm normalized name: flunitrazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1 mg
Trial: 11519634
Drug: Diazepam 20
RxNorm normalized name: diazePAM 20 mg rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 20 mg
Trial: 2223425
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg
Trial: 1589558
Drug: Flunitrazepam 1
RxNorm normalized name: flunitrazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1 mg and Diazepam 20 mg
Trial: 1589558
Drug: Flunitrazepam treatments
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam treatments
Trial: 23540189
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no rHuEPO, received oral iron and folic acid from day 14)
Trial: 7657846
Drug: Flecainide 200
RxNorm normalized name: flecainide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 200 mg/day
Trial: 23466591
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate 10 g daily
Trial: 12091294
Drug: Moderately early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately early postnatal dexamethasone treatment (4.75 mg/kg over 14 days from the 10th day of life)
Trial: 7854168
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) at a dose of 0.25 to 0.5 U/kg/wk, administered subcutaneously once a day in the evening.
Trial: 7854168
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) treatment.
Trial: 22108473
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pycnogenol® and compression stockings (group 3)
Trial: 22108473
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pycnogenol® and compression stockings
Trial: 15588339
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) 200 mg qd
Trial: 15588339
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) 200 mg qd in HIV-infected patients
Trial: 15588339
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) 200 mg/day
Trial: 11907840
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate foam (BMV foam), 0.12%, applied twice daily for 12 weeks
Trial: 11907840
Drug: Placebo foam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo foam, applied twice daily for 12 weeks
Trial: 9735502
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with protease inhibitors (PI)
Trial: 3365458
Drug: MK-212 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-212 20 mg
Trial: 3365458
Drug: MK-212 40
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-212 40 mg
Trial: 3365458
Drug: MK-212 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-212 (10, 20, 40 mg)
Trial: 21210338
Drug: Zolpidem (0.14-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (0.14-0.2 mg/kg daily for 4 days)
Trial: 21210338
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 4 days)
Trial: 2566251
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg kg‐1
Trial: 7999489
Drug: Mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.15 mg kg‐1
Trial: 9861140
Drug: Mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.2 mg kg‐1
Trial: 28619
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg/day)
Trial: 30081859
Drug: Baseline (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (no treatment)
Trial: 95729
Drug: Intranasal luteinising-hormone
RxNorm normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal luteinising-hormone releasing hormone (L.H.R.H.) administered in six doses daily (1.2 mg/day) for four weeks
Trial: 10788675
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment
Trial: 11962682
Drug: Chronomodulated chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronomodulated chemotherapy (B)
Trial: 2246042
Drug: Prenatal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal iron supplements (oral or parenteral)
Trial: 2246042
Drug: Parenteral iron
RxNorm normalized name: Iron, parenteral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral iron
Trial: 556551
Drug: Cyclic polychemotherapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic polychemotherapy (cyclophosphamide, mercaptopurine, prednisolone, dipyridamol, heparin)
Trial: 556551
Drug: Continuous two-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous two-drug regimen (mercaptopurine + prednisolone)
Trial: 25881677
Drug: Sumatriptan/Naproxen Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan/Naproxen Sodium (S/NS) 85/500 mg
Trial: 14982688
Drug: Bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride sustained-release (Zyban)
Trial: 10910479
Drug: Rocuronium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.4 mg/kg
Trial: 9416722
Drug: Rocuronium 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.8 mg/kg
Trial: 17312208
Drug: Rocuronium 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 1.2 mg/kg
Trial: 2688507
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEpo) therapy
Trial: 23768736
Drug: Nebulizer with
RxNorm normalized name: AeroNeb Go Nebulizer with Cable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer with Combivent (2.5 mg salbutamol and 250 mcg ipratropium per mL)
Trial: 16384759
Drug: Combination clindamycin
RxNorm normalized name: clindamycin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination clindamycin (1%) and tretinoin (0.025%) hydrogel
Trial: 8360134
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (50 mg/day as a single dose)
Trial: 8824962
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole
Trial: 8360134
Drug: Oral polyenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polyenes
Trial: 3090906
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) at doses up to 40 micrograms X kg‐1 X min‐1
Trial: 3090906
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) at doses of 6‐8 micrograms X kg‐1 X min‐1
Trial: 26945711
Drug: Atazanavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir monotherapy
Trial: 26945711
Drug: Atazanavir/ritonavir triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir triple therapy
Trial: 25679130
Drug: Slow-release oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oral morphine (SROM)
Trial: 21633047
Drug: Standard-dose XT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose XT (capecitabine 1250 mg/m² twice daily, days 1-14; docetaxel 75 mg/m², day 1 every 3 weeks)
Trial: 21633047
Drug: Low-dose XT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose XT (capecitabine 825 mg/m² twice daily, days 1-14; docetaxel as above)
Trial: 12867219
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 tablet BID)
Trial: 8166033
Drug: Di‐Gel Lemon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Di‐Gel Lemon Orange
Trial: 24135218
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker
Trial: 24135218
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with either angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker
Trial: 21438793
Drug: fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibric acid + moderate-dose statin
Trial: 21438793
Drug: fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibric acid + low-dose statin
Trial: 21438793
Drug: fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibric acid + low- and moderate-dose statin
Trial: 31577697
Drug: YGJT (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YGJT (3g twice a day for 4 weeks) + nutrition counseling
Trial: 23442225
Drug: VA (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VA (2000 IU daily retinol)
Trial: 23442225
Drug: VD (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VD (400 IU daily cholecalciferol)
Trial: 23442225
Drug: VAD (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAD (2000 IU daily retinol plus 400 IU cholecalciferol)
Trial: 21466079
Drug: Video condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video condition (participants who watched a video of their precompetition preparation)
Trial: 8410923
Drug: Lisinopril vs
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril vs Placebo
Trial: 3776903
Drug: Intravenous 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous 5-FU
Trial: 28970291
Drug: EBL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBL plus propranolol (EBL+drug)
Trial: 20573348
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus (40 mg vaginal application once weekly for 6 months)
Trial: 15845315
Drug: Overall (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (all treatments)
Trial: 9478315
Drug: 17-alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-alpha-hydroxyprogesterone caproate (341 mg once a week)
Trial: 9478315
Drug: Natural Progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural Progesterone (50 mg/day)
Trial: 29665062
Drug: 3% JTE-052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% JTE-052 ointment
Trial: 24767638
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 1 mg/mL ropivacaine and 2 μg/mL fentanyl (Group A)
Trial: 24767638
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.8 mg/mL bupivacaine (Group B)